Trials / Recruiting
RecruitingNCT07215312
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin
A Phase 2, Randomized, Open-Label, Comparator-Controlled Trial to Evaluate the Efficacy and Safety of LY3938577 in Study Participants, With Type 2 Diabetes Previously Treated With Basal Insulin
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to see how well LY3938577 works and how safe it is compared to degludec in people with type 2 diabetes. Participation in the study will last about 26 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3938577 | Administered SC |
| DRUG | Degludec | Administered SC |
Timeline
- Start date
- 2025-10-13
- Primary completion
- 2026-11-01
- Completion
- 2026-12-01
- First posted
- 2025-10-10
- Last updated
- 2026-04-17
Locations
26 sites across 2 countries: United States, Argentina
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07215312. Inclusion in this directory is not an endorsement.